

**XP-002204207**

**AN - 1990-151821 [25]**

**AP - JP19880190637 19880801 JP19880190637 19880801; [Previous Publ. J02096535 ]**

**CPY - CHUS**

**DC - B04 B05**

**FS - CPI**

**IC - A61K37/02 ; A61K38/00**

**MC - B04-B04A6 B12-H01**

**M1 - [01] M423 M781 M903 P812 V624; 1327-U 0502-U**

**PA - (CHUS ) CHUGAI PHARM CO LTD**

**PN - JP2096535 A 19900409 DW199020 000pp**

**- JP2632014B2 B2 19970716 DW199733 A61K38/00 006pp**

**PR - JP19880048632 19880303; JP19880190637 19880801**

**XA - C1990-066289**

**XIC - A61K-037/02 ; A61K-038/00**

**AB - J02096535 Therapeutic agent for anaemia caused from bone marrow function, contains as active substance, human erythropoietin. Pref. the human erythropoietin is prepd. by gene expression of gene in host, encoding aminoacid sequence of human erythropoietin, which is obtd. from human urine. Carcinostatic substance is cisplatin, 5-fluorouracyl, merphalan, cyclophosphamide, busulphan, cytarabine, mercaptopurine, doxorubicin, aclarubicin, mitomycin C, actinomycin D or etoposide. Therapeutic agent is used for redn. of side-effects of administration of carcinostatic substance. Dose of human erythropoietin H-EPO) is 500-100000 U/day. Therapeutic agent is in form of intravenous or subcutaneous injection.**

**- USE/ADVANTAGE - For therapy of anaemia due to radiation exposure or administration of carcinostatic substance.**

**- (Dwg.0/0)**

**DRL - 1327-U 0502-U**

**IW - THERAPEUTIC AGENT ANAEMIA CONTAIN HUMAN ERYTHROPOIETIN ACTIVE SUBSTANCE CARCINOSTATIC SUBSTANCE SIDE EFFECT REDUCE**

**IKW - THERAPEUTIC AGENT ANAEMIA CONTAIN HUMAN ERYTHROPOIETIN ACTIVE SUBSTANCE CARCINOSTATIC SUBSTANCE SIDE EFFECT REDUCE**

**NC - 001**

**OPD - 1988-03-03**

**ORD - 1990-04-09**

**PAW - (CHUS ) CHUGAI PHARM CO LTD**

**TI - Therapeutic agent for anaemia - contg. human erythropoietin as active substance, for carcinostatic substance side-effect redn. etc.**